\
&
Contact us
\
&
Contact us
Published on | 1 month ago
ProgrammesWomen TechEU 2 EIC is an EU-funded programme designed to support women-led early-stage deep tech start-ups in Europe. Selected start-ups are expected to receive €75,000 in non-dilutive funding, alongside a personalised business development programme that includes mentoring, coaching and training.
The new call uses a two-stage application process. Applicants must first complete the Eligibility Strand, which is designed to check whether they meet the programme’s participation requirements. Only eligible applicants will be invited to submit a full proposal.
The Eligibility Strand opens on 1 June 2026. Cut-offs will take place weekly on Tuesdays at 17:00 (Brussels time). The first cut-off is on 30 June 2026 at and the final cut-off is on 13 July 2027.
If you are interested, please visit this website. Applicants are encouraged to read the Guidelines for Applicants carefully and submit well before the relevant deadline.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
